The Food and Drug Administration (FDA) has approved a labeling update for Vemlidy (tenofovir alafenamide; Gilead Sciences) to include dosage information regarding its use in adults with end-stage renal disease (ESRD; CrCl <15mL/min) who are receiving chronic hemodialysis.
The researchers found that an estimated 1% absolute increase in quarterly ILI correlated with a 1.5% increase and a 2.0% increase in relative mortality for quarters 4 and 1, respectively.
Temixys combines lamivudine (3TC) and tenofovir disoproxil fumarate (TDF), which are 2 nucleoside reverse transcriptase inhibitors.
Drugs in the Pipeline
Intradialytic hypotension is a common complication of hemodialysis and can lead to increased morbidity and mortality among patients with end-stage renal disease.
"CKD staged by level of eGFR and proteinuria characterizes the timeline of progression and can guide management strategies in children," the authors write.
AHA 2017 Scientific Sessions
End-stage renal disease patients on dialysis with atrial fibrillation are at high risk for thrombotic complications.
Uric acid-lowering therapy might improve kidney outcomes, including kidney failure events, proteinuria, and the rate of change in eGFR, and seem to reduce the risk of cardiovascular events in adults with CKD.
Shorter sleep duration, greater sleep fragmentation linked to greater decline in eGFR
Dialyzed patients have higher in-hospital mortality, hemorrhagic complications after RFA for HCC
Total of 26.6 and 27 percent of patients experienced anxiety, depression with initiation of RRT